share_log

Viking Therapeutics | 10-Q: Q2 2024 Earnings Report

Viking Therapeutics | 10-Q: Q2 2024 Earnings Report

Viking Therapeutics | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/25 05:05

Moomoo AI 已提取核心訊息

Viking Therapeutics reported financial results for Q2 2024, with a net loss of $22.3 million ($0.20 per share) compared to $19.2 million ($0.19 per share) in Q2 2023. Research and development expenses increased 70.8% to $23.8 million, primarily due to expanded clinical studies and manufacturing activities for drug candidates. The company ended the quarter with $942.3 million in cash and investments.The company made significant progress across its pipeline, including positive Phase 2 VENTURE study results for VK2735 in obesity and Phase 2b VOYAGE trial results for VK2809 in NASH. General and administrative expenses rose 4.7% to $10.3 million, while interest income increased substantially to $11.8 million from $4.5 million in the prior year period.Looking ahead, Viking plans to initiate a Phase 3 trial for subcutaneous VK2735 in obesity and a Phase 2 trial for oral VK2735 later in 2024. The company believes its current cash position will fund operations through at least September 2025. Management continues to focus on advancing its metabolic disorder pipeline while maintaining a strong financial position.
Viking Therapeutics reported financial results for Q2 2024, with a net loss of $22.3 million ($0.20 per share) compared to $19.2 million ($0.19 per share) in Q2 2023. Research and development expenses increased 70.8% to $23.8 million, primarily due to expanded clinical studies and manufacturing activities for drug candidates. The company ended the quarter with $942.3 million in cash and investments.The company made significant progress across its pipeline, including positive Phase 2 VENTURE study results for VK2735 in obesity and Phase 2b VOYAGE trial results for VK2809 in NASH. General and administrative expenses rose 4.7% to $10.3 million, while interest income increased substantially to $11.8 million from $4.5 million in the prior year period.Looking ahead, Viking plans to initiate a Phase 3 trial for subcutaneous VK2735 in obesity and a Phase 2 trial for oral VK2735 later in 2024. The company believes its current cash position will fund operations through at least September 2025. Management continues to focus on advancing its metabolic disorder pipeline while maintaining a strong financial position.
Viking Therapeutics發佈了2024年第二季度的財務結果，淨虧損爲$2230萬（每股$0.20），相比之下，2023年第二季度的淨虧損爲$1920萬（每股$0.19）。研發費用增加了70.8%，達到了$2380萬，主要由於擴大了臨牀研究和藥物候選者的製造業活動。公司在本季度結束時現金和投資總額爲$94230萬。公司在其產品管線中取得了顯著進展，包括VK2735在肥胖症的積極Phase 2 創業公司的研究結果，以及VK2809在NASH中的Phase 20億 VOYAGE試驗結果。一般和行政費用上升了4.7%，達到了$1030萬，而利息收入則大幅增加，達到了$1180萬，相比之下...展開全部
Viking Therapeutics發佈了2024年第二季度的財務結果，淨虧損爲$2230萬（每股$0.20），相比之下，2023年第二季度的淨虧損爲$1920萬（每股$0.19）。研發費用增加了70.8%，達到了$2380萬，主要由於擴大了臨牀研究和藥物候選者的製造業活動。公司在本季度結束時現金和投資總額爲$94230萬。公司在其產品管線中取得了顯著進展，包括VK2735在肥胖症的積極Phase 2 創業公司的研究結果，以及VK2809在NASH中的Phase 20億 VOYAGE試驗結果。一般和行政費用上升了4.7%，達到了$1030萬，而利息收入則大幅增加，達到了$1180萬，相比之下去年同期爲$450萬。展望未來，Viking計劃於2024年晚些時候開始VK2735的皮下Phase 3試驗以及VK2735的口服Phase 2試驗。公司相信其當前的現金狀況將能支撐運營至少到2025年9月。管理層繼續專注於推進其代謝疾病的產品管線，同時保持強勁的財務狀況。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間